Clinical and laboratory characteristics of studied MDS patients
| Patient no. . | Age, y . | FAB classification . | Hemoglobin, mmol/L* . | Leucocytes, ×109/L . | Platelets, ×109/L . | Bone marrow cellularity . | Cytogenetics . | Transfusion dependence . | Treatment . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 62 | RARS | 4.5 | 2.9 | 153 | ++ | 47,XY,+19 | + | − |
| 2 | 69 | RARS | 6.0 | 6.5 | 285 | ++ | N | − | Cyclosporine |
| 3 | 58 | RARS | 6.0 | 4.1 | 376 | ++ | N | − | Oxymethol |
| 4 | 21 | RA | 6.5 | 3.4 | 20 | ++ | N | − | Oxymethol |
| 5 | 34 | RA | 4.5 | 4.4 | 475 | ++ | N | + | − |
| 6 | 70 | RA | 5.5 | 3.6 | 70 | ++ | N | + | − |
| 7 | 44 | RA | 5.5 | 1.4 | 70 | ++ | N | − | − |
| 8 | 55 | RARS | 5.0 | 1.1 | 108 | ++ | N | + | Erythropoietin |
| 9 | 70 | RARS | 5.2 | 6.2 | 410 | ++ | 45,X,-Y | − | Erythropoietin |
| 10 | 36 | RA | 5.8 | 7.5 | 30 | ++ | 46,XY,i(17) | + | − |
| 11 | 57 | RA | 5.1 | 4.3 | 228 | ++ | N | − | Erythropoietin |
| 12 | 72 | RA | 6.1 | 5.8 | 406 | ++ | N | + | Oxymetholone |
| 13 | 60 | RA | 6.6 | 2.8 | 62 | ++ | N | − | Erythropoietin |
| 14 | 21 | RA | 6.0 | 1.5 | 60 | ++ | 45,XY, −7(20) | − | − |
| 15 | 68 | RARS | 4.4 | 2.4 | 64 | ++ | 45,X-Ydup(1) (q21q32)(3)/ 45,XY,-Y(7) | + | Erythropoietin |
| 16 | 64 | RA | 6.6 | 9.0 | 700 | ++ | N | − | Danazol |
| 17 | 84 | RA | 5.7 | 6.8 | 163 | ++ | N | + | − |
| Patient no. . | Age, y . | FAB classification . | Hemoglobin, mmol/L* . | Leucocytes, ×109/L . | Platelets, ×109/L . | Bone marrow cellularity . | Cytogenetics . | Transfusion dependence . | Treatment . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 62 | RARS | 4.5 | 2.9 | 153 | ++ | 47,XY,+19 | + | − |
| 2 | 69 | RARS | 6.0 | 6.5 | 285 | ++ | N | − | Cyclosporine |
| 3 | 58 | RARS | 6.0 | 4.1 | 376 | ++ | N | − | Oxymethol |
| 4 | 21 | RA | 6.5 | 3.4 | 20 | ++ | N | − | Oxymethol |
| 5 | 34 | RA | 4.5 | 4.4 | 475 | ++ | N | + | − |
| 6 | 70 | RA | 5.5 | 3.6 | 70 | ++ | N | + | − |
| 7 | 44 | RA | 5.5 | 1.4 | 70 | ++ | N | − | − |
| 8 | 55 | RARS | 5.0 | 1.1 | 108 | ++ | N | + | Erythropoietin |
| 9 | 70 | RARS | 5.2 | 6.2 | 410 | ++ | 45,X,-Y | − | Erythropoietin |
| 10 | 36 | RA | 5.8 | 7.5 | 30 | ++ | 46,XY,i(17) | + | − |
| 11 | 57 | RA | 5.1 | 4.3 | 228 | ++ | N | − | Erythropoietin |
| 12 | 72 | RA | 6.1 | 5.8 | 406 | ++ | N | + | Oxymetholone |
| 13 | 60 | RA | 6.6 | 2.8 | 62 | ++ | N | − | Erythropoietin |
| 14 | 21 | RA | 6.0 | 1.5 | 60 | ++ | 45,XY, −7(20) | − | − |
| 15 | 68 | RARS | 4.4 | 2.4 | 64 | ++ | 45,X-Ydup(1) (q21q32)(3)/ 45,XY,-Y(7) | + | Erythropoietin |
| 16 | 64 | RA | 6.6 | 9.0 | 700 | ++ | N | − | Danazol |
| 17 | 84 | RA | 5.7 | 6.8 | 163 | ++ | N | + | − |
FAB indicates French-American-British Classification; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess of blasts; ++, normal or increased cellularity; N, no abnormalities; +, transfusion-dependent; and −, not transfusion dependent.
To convert hemoglobin mmol/L to g/L, multiply by factor 1.5.